Application of liver-soothing and qi-guiding composition in preparation of antidepressant drugs

Through different preparation methods of the Shugan Shunqi composition, the problems of low efficiency and serious adverse reactions of existing antidepressants were solved, significantly improved the therapeutic effect of depression, and verified its efficacy through animal and clinical trials, especially in Remarkable results have been achieved in phase extraction and pH adjustment of distilled oil.

CN118948986AActive Publication Date: 2024-11-15CHONGQING HILAN PHARM CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411032665.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-15
Estimated Expiration
2044-07-30

AI Technical Summary

Technical Problem

The existing antidepressant drugs have problems such as low efficiency, single pathways and serious adverse reactions in the treatment of depression. The use and indications of Shugan Shunqi Pills need to be further developed.

Method used

Using the composition of Soogenic Suppression and Qi, made of medicinal materials such as Magnolia officinalis, Chuanxiong, Xiangfu, Baishao, Bupleurum, Citrus aurantium, Tulip, Buddha's hand, Muxiang, Tangerine peel, licorice and Malan grass, through different preparation methods Such as powdering preparations, ethanol extract preparations, distillation and decoction extraction preparations, to improve the antidepressant effect of the drug.

Benefits of technology

The Shugan Shunqi composition significantly improves the symptoms of functional dyspepsia with depression. Its efficacy in the treatment of depression has been confirmed through animal experiments and clinical trials. Different preparation methods have a significant impact on the effect of the drug, especially in controlling the distilled oil phase. The therapeutic effect is further improved during extraction and pH adjustment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_4
    Figure SMS_4
Patent Text Reader

Abstract

The invention relates to the technical field of depression treatment medicines, in particular to application of a liver-soothing and qi-guiding composition in preparation of antidepressant medicines. The traditional Chinese medicine composition for soothing liver and guiding qi mainly has the functions of soothing liver, regulating qi and relieving pain, has an exact clinical curative effect, has a small adaptation disease range, and needs to be further developed. The invention further provides application of the liver-soothing and qi-guiding composition in the aspects of improving the depression state and treating depression, and the liver-soothing and qi-guiding composition especially has an ideal effect on treatment of dyspepsia with depression diseases. In addition, according to the technical scheme, improvement is carried out on the basis of an original liver-soothing and qi-guiding pill, the dissolution rate of effective components in the composition is further improved through improvement of the preparation technology, and addition of a large amount of honey in an original liver-soothing and qi-guiding preparation is avoided while preparation is carried out. And the problems of limited drug use crowds and poor medication compliance of patients are solved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of drugs for treating depression, and in particular to use of a liver-soothing and qi-regulating composition in preparing antidepressant drugs. Background Art

[0002] Depression, also known as depressive disorder in clinical practice, is a significant psychological illness characterized by low mood, mainly manifested by low mood, decreased interest, slow thinking, decreased attention and memory, as well as physical symptoms such as decreased appetite and sleep disorders. Depression seriously troubles the patient's life and work, and brings a heavy burden to the family and society.

[0003] In the clinical treatment of depression, Western medicine clinical antidepressants represented by fluoxetine, paroxetine and other 5-hydroxytryptamine (HT) reuptake inhibitors have clear targets and rapid efficacy, but they also have disadvantages such as low efficiency, single pathway, and serious adverse reactions. With the continuous development of modern research on traditional Chinese medicine, the classical theories of traditional Chinese medicine are gradually being integrated with modern medicine. Traditional Chinese medicine has shown unique advantages in the clinical prevention and treatment of depression. In comparison, traditional Chinese medicine for the treatment of depression is relatively slow in onset, mild in efficacy, with fewer adverse reactions and better long-term treatment efficacy. Commonly used traditional Chinese medicines for depression include Shugan Jieyu Capsules, Jieyu Anshen Granules, Chaihu Shugan Powder, Xiaoyao Powder, Danzhi Xiaoyao Powder, and Chinese patent medicine Jieyu Pills. The characteristics of traditional Chinese medicine for the treatment of depression are small side effects, which can effectively improve mild depression and anxiety, and have a certain improvement effect on sleep. When used in combination with Western medicine, the effect is better.

[0004] Shugan Shunqi Pills are a pure Chinese medicine preparation composed of 13 Chinese herbs, including Bupleurum, vinegar-processed Cyperus rotundus, white peony root, Curcuma aromatica, stir-fried Citrus aurantium, Magnolia officinalis, costusroot, Citrus citron, vinegar-processed Corydalis, Chuanxiong, Amaranthus, Tangerine peel, and Licorice. Shugan Shunqi Pills are large black honey pills, and their functions and indications are: soothing the liver, regulating qi, and relieving pain; they are used for symptoms of liver depression and qi stagnation, with symptoms of: fullness in both flanks, stabbing pain in the stomach, vomiting and noisy, belching and acid reflux. Experimental studies have shown that Shugan Shunqi Pills can effectively improve the symptoms of functional dyspepsia model and gastrointestinal motility disorder model, inhibit gastric acid secretion, promote gastrointestinal motility, improve serum gastrointestinal hormone levels, increase pepsin activity, and have obvious pharmacological effects of increasing intestinal absorption and analgesia.

[0005] In addition to the aforementioned therapeutic effects, literature indicates that Shugan Shunqi Pills also have the following therapeutic effects: Shugan Shunqi Pills can dissolve cholesterol stones and bile pigment stones, inhibit the formation of new stones, and promote the appearance of high-amplitude interval peak potentials to varying degrees, suggesting that Shugan Shunqi Pills may have a better therapeutic effect on liver dysfunction and yang juice dysfunction (Chen Li, Lu Shanshan, Qiao Zhiwen, et al. Study on the choleretic pharmacodynamics of Shugan Shunqi Pills [J]. World Journal of Integrated Traditional and Western Medicine, 2014, 9(12): 1281-1284.). In addition, Shugan Shunqi Pills also have good anti-inflammatory effects and can significantly improve pathological changes such as swelling and hyperplasia caused by inflammation. It has a certain effect on the treatment of superficial gastritis and other digestive tract inflammations (Qiao Zhiwen, Chen Li, Lu Shanshan, et al. Study on the anti-inflammatory effect of Shugan Shunqi Pills [J]. Chinese Pharmacy, 2013, 24(47): 4444-4446.).

[0006] Shugan Shunqi Pills have a wide range of clinical applications, definite efficacy, and are widely praised by patients. However, there is no relevant research on it in the field of anti-depression, and its clinical application needs to be further explored to meet the needs of clinical treatment of depression. Summary of the invention

[0007] The present invention is intended to provide an application of a Shugan Shunqi composition in the preparation of an antidepressant drug, so as to solve the technical problem that the uses and indications of the Shugan Shunqi pills in the prior art need to be further developed.

[0008] In order to achieve the above object, the present invention adopts the following technical scheme:

[0009] Application of a soothing and relieving qi composition in the preparation of an antidepressant, the soothing and relieving qi composition being prepared from the following medicinal raw materials in parts by weight: 25-35 parts of Magnolia officinalis, 25-35 parts of Chuanxiong, 25-35 parts of Cyperus rotundus, 25-35 parts of White Peony Root, 25-35 parts of Bupleurum Root, 25-35 parts of Citrus aurantium, 25-35 parts of Curcuma Radix, 25-35 parts of Citrus Hand, 25-35 parts of Aucklandia Root, 25-35 parts of Tangerine Peel, 20-30 parts of Licorice, 25-35 parts of Corydalis yanhusuo and 45-60 parts of Amaranthus chinensis;

[0010] Preferably, the liver-soothing and qi-relief composition is made of the following medicinal raw materials in the following parts by mass: 31.4 parts of Magnolia officinalis, 31.4 parts of Chuanxiong, 31.4 parts of Cyperus rotundus, 31.4 parts of White Peony Root, 31.4 parts of Bupleurum Root, 31.4 parts of Citrus aurantium, 31.4 parts of Curcuma aromatica, 31.4 parts of Citrus citrus hand, 31.4 parts of Aucklandia lappa, 31.4 parts of Tangerine peel, 23.55 parts of Licorice, 31.4 parts of Corydalis yanhusuo and 58.85 parts of Amaranthus grandiflora.

[0011] The technical scheme also provides an application of a soothing and relieving qi composition in the preparation of a drug for improving, assisting in the treatment or treating functional dyspepsia with depression, wherein the soothing and relieving qi composition is prepared from the following medicinal raw materials by weight: 25-35 parts of Magnolia officinalis, 25-35 parts of Chuanxiong, 25-35 parts of Cyperus rotundus, 25-35 parts of White Peony Root, 25-35 parts of Bupleurum Root, 25-35 parts of Citrus aurantium, 25-35 parts of Curcuma aromatica, 25-35 parts of Citrus citron, 25-35 parts of Aucklandia lappa, 25-35 parts of Tangerine peel, 20-30 parts of Licorice, 25-35 parts of Corydalis yanhusuo and 45-60 parts of Amaranthus chinensis.

[0012] Preferably, the liver-soothing and qi-relief composition is made of the following medicinal raw materials in the following parts by mass: 31.4 parts of Magnolia officinalis, 31.4 parts of Chuanxiong, 31.4 parts of Cyperus rotundus, 31.4 parts of White Peony Root, 31.4 parts of Bupleurum Root, 31.4 parts of Citrus aurantium, 31.4 parts of Curcuma aromatica, 31.4 parts of Citrus citrus hand, 31.4 parts of Aucklandia lappa, 31.4 parts of Tangerine peel, 23.55 parts of Licorice, 31.4 parts of Corydalis yanhusuo and 58.85 parts of Amaranthus grandiflora.

[0013] Furthermore, the dosage form of the liver-soothing and qi-regulating composition is any one of pills, granules, tablets, oral liquid or capsules.

[0014] Furthermore, the liver-soothing and qi-regulating composition is prepared according to the following method:

[0015] S1-1: Take each medicinal material according to the formula, grind each medicinal material and pass it through an 80-120 mesh sieve, mix them evenly, and obtain the active ingredient of the medicine;

[0016] S1-2: Adding pharmaceutical excipients to the active ingredient of the drug to prepare it into a clinically acceptable oral preparation.

[0017] Furthermore, the liver-soothing and qi-regulating composition is prepared according to the following method:

[0018] S2-1: Take thirteen medicinal materials according to the formula and set aside;

[0019] S2-2: 1 / 2 to 2 / 3 of the weight of each medicinal material is crushed into fine powder through a 80-120 mesh sieve, and the coarse powder and fine powder after sieving are set aside separately;

[0020] S2-3: Grind the remaining medicinal materials into coarse powder;

[0021] S2-4: the coarse powder and the coarse head are mixed, an ethanol solution of 6 to 8 times the total weight of the coarse powder and the coarse head is added, and the mixture is immersed at a temperature of 40 to 60° C. for 30 to 90 minutes, followed by a first reflux extraction for 1 to 2 hours, and then an ethanol solution of 6 to 8 times the total weight of the coarse powder and the coarse head is added for a second reflux extraction for 1 to 2 hours, the extracts are combined, ethanol is recovered under reduced pressure, filtered, the residue is recovered, and the extract is concentrated to extract I, wherein the concentration of the ethanol solution used in the extraction is 45 to 65%;

[0022] S2-5: decoct the residue obtained after extraction with water for 2 to 3 times, with the amount of water added each time being 6 to 10 times the amount of the residue, for 1 to 3 hours each time, combine the decoctions, filter, and concentrate the obtained filtrate to extract II, combine extract I and extract II, add the fine powder obtained in step S22, mix well, and obtain the active ingredient of the drug;

[0023] S2-6: Add pharmaceutical excipients to the active ingredient to prepare it into a clinically acceptable preparation.

[0024] Furthermore, the liver-soothing and qi-regulating composition is prepared according to the following method:

[0025] S3-1: Take thirteen medicinal materials according to the formula and set aside;

[0026] S3-2: The medicinal raw materials are extracted by distillation to obtain a distilled water phase, a distilled oil phase and a medicinal residue, the medicinal residue is extracted by decocting in water to obtain a decoction, the decoction and the distilled water phase are combined to obtain an extract, the extract is concentrated into an extract, and the extract, the distilled oil phase and suitable excipients are prepared into a clinically acceptable oral dosage form.

[0027] Furthermore, the liver-soothing and qi-regulating composition is prepared according to the following method:

[0028] S4-1: 13 medicinal materials are taken according to the formula and set aside for use. The medicinal materials are subjected to distillation extraction to obtain a distilled water phase, a distilled oil phase and medicinal residues. The medicinal residues are subjected to water decoction extraction to obtain a decoction liquid, and the decoction liquid and the distilled water phase are combined to obtain an extract;

[0029] S4-2: using an inclusion agent to carry out inclusion treatment on the distilled oil phase to obtain inclusion compound powder or inclusion compound solution;

[0030] S4-3: After the extract is concentrated, it is prepared into a clinically acceptable oral dosage form with inclusion compound powder or inclusion compound solution and appropriate excipients.

[0031] Further, in S4-1, the method for extracting the medicinal residue by decoction in water is as follows: adding water 6 to 8 times the mass of the medicinal raw material for a first decoction extraction for 2 to 3 hours; adding water 6 to 8 times the mass of the medicinal raw material and adjusting the pH value to 7.0 to 7.5, and performing a second decoction extraction for 2 to 3 hours.

[0032] Further, in S4-1, the distillation extraction adopts an intermittent distillation extraction method, and the intermittent distillation extraction is performed alternately by fierce fire distillation and slight boiling distillation;

[0033] Preferably, the intermittent distillation extraction uses water or alcohol solution as the extraction solvent; preferably, the total extraction time is 1 to 8 hours; preferably, the extraction process of the intermittent distillation extraction is cyclically carried out in a manner of first 10 to 20 minutes of high-fire distillation extraction and then 10 to 20 minutes of micro-boiling distillation extraction.

[0034] Further, in S4-2, hydroxypropyl-β-cyclodextrin is used as an inclusion agent to carry out inclusion treatment on the distilled oil phase;

[0035] Preferably, the inclusion treatment method is: take an inclusion agent of 3 to 5 times the mass of the distilled oil phase, dissolve it, and then add the distilled oil phase at a rate of 1 to 2 ml / min under stirring conditions of 40 to 60 rpm, and stir for 1.5 to 2.5 hours after the addition is completed to obtain an inclusion solution; concentrate and dry it to a moisture content of less than 5.0%, and then crush it through an 80 to 100 mesh sieve to obtain an inclusion powder.

[0036] The present invention provides a liver-soothing and gas-regulating composition, the principle and beneficial effects of which are:

[0037] This technical solution has conducted a lot of research on the new use and preparation process of the Shugan Shunqi composition, and found that the Shugan Shunqi composition has application value beyond the original efficacy. It can be used for the treatment of depression, especially in clinical practice, it can effectively improve the symptoms of functional dyspepsia accompanied by anti-depression, and the inventor has further confirmed the above-mentioned efficacy of the Shugan Shunqi composition through animal experiments and clinical trials. In addition, the inventor also found that the use of the same drug raw materials but different preparation methods has a certain effect on the anti-depressant effect of the drug. In this regard, the inventor has compared different preparation methods, including: from crude drug powder preparations, to crude drug ethanol extract preparations, and then to crude drug distillation and decoction extraction preparations, step by step to improve the effect of the drug on improving depression. In the process of crude drug distillation and decoction extraction preparations, the inventor further includes the distilled oil phase appropriately, and controls the pH value during the decoction extraction process, which can further improve the efficacy of the Shugan Shunqi preparation in the treatment of depression.

[0038] Anxiety and depression are two common but different mental health conditions. Although they often occur in the same individual at the same time and have some overlap in symptoms, they are significantly different in clinical manifestations, pathogenesis, and treatment methods. In terms of clinical manifestations, anxiety disorders are mainly manifested as worries, fears, nervousness, and excessive attention to potential threats about the future. They may be accompanied by physical symptoms such as palpitations, rapid heartbeats, sweating, tremors, muscle tension, headaches, and stomach discomfort. Patients may experience sleep disorders, such as difficulty falling asleep or frequent awakenings. They may manifest as motor restlessness such as fidgeting, pacing, or rubbing hands and feet. Depression is mainly manifested by persistent low mood, loss of interest and happiness, and decreased self-worth. Thinking may become slow, lack motivation, and lose interest in daily activities. Excessive sleep or insomnia, changes in appetite, weight fluctuations, fatigue, or lack of energy may occur. Patients with depression may have suicidal thoughts or behaviors. The diagnostic criteria and reference scales of the two diseases are different, so it is very important and necessary to develop new treatment approaches and drugs for the two different mental illnesses. This technical solution is particularly targeted at depression and it is found that the liver-soothing and qi-smoothing composition has a good therapeutic effect on depression. DETAILED DESCRIPTION

[0039] The specific embodiments listed in the present invention are only examples of the present invention, and the present invention is not limited to the specific embodiments described below. For those skilled in the art, any equivalent modifications and substitutions made to the embodiments described below are also within the scope of the present invention. Therefore, the equalization and modification made without departing from the spirit and scope of the present invention should be included in the scope of the present invention.

[0040] In the examples, if the specific conditions are not specified, the conditions are carried out according to normal conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified for all reagents or instruments, they are all conventional products that can be purchased commercially. In order to better illustrate the present invention, numerous specific details are provided in the specific embodiments below. It should be understood by those skilled in the art that the present invention can be implemented equally without certain specific details. In other embodiments, methods, means, equipment and steps well known to those skilled in the art are not described in detail to highlight the gist of the present invention.

[0041] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art. Unless otherwise specified, the units used in this specification are all international standard units, and the numerical values ​​and numerical ranges appearing in the present invention should be understood to include the inevitable systematic errors in industrial production.

[0042] The specific formula of the liver-soothing and qi-regulating composition is as follows:

[0043] 25-35 parts of Magnolia officinalis, 25-35 parts of Chuanxiong, 25-35 parts of Cyperus rotundus (vinegar-processed), 25-35 parts of white peony root, 25-35 parts of Bupleurum root, 25-35 parts of Immature Citrus aurantium (fried), 25-35 parts of Curcuma, 25-35 parts of Citrus hand, 25-35 parts of Aucklandia lappa, 25-35 parts of Tangerine peel, 20-30 parts of Licorice, 25-35 parts of Corydalis (vinegar-fried), 45-60 parts of Amaranthus (Wedelia). This technical solution is mainly studied for drug use, and the formula composition is not adjusted. For the convenience of experimental research, the subsequent experimental content uniformly adopts a consistent formula, specifically referring to the formula in the embodiment. The above formula and value range can be used to achieve the therapeutic effect on depression.

[0044] Example 1

[0045] This embodiment provides a method for preparing a Shugan Shunqi preparation, which prepares the medicinal raw materials into pills with reference to the existing Shugan Shunqi pill standards. Specifically, the medicinal raw materials are:

[0046] 31.4 parts of Magnolia officinalis, 31.4 parts of Chuanxiong, 31.4 parts of Cyperus rotundus (vinegar-processed), 31.4 parts of White Peony Root, 31.4 parts of Bupleurum Root, 31.4 parts of Fructus Aurantii Immaturus (fried), 31.4 parts of Curcuma Radix, 31.4 parts of Citrus Palmito, 31.4 parts of Aucklandiae Radix, 31.4 parts of Tangerine Peel, 23.55 parts of Licorice, 31.4 parts of Corydalis (vinegar-processed), and 58.85 parts of Amaranthus;

[0047] The preparation method is as follows:

[0048] (01) Taking each medicinal material according to the above weight proportions for later use, crushing each medicinal material and passing it through a 100-mesh sieve (a 80-120-mesh sieve can be used in actual operation), mixing them evenly, and obtaining the active ingredient of the medicine;

[0049] (02) Add an appropriate amount of adhesive (the adhesive is starch paste) to the active ingredient of the drug to prepare it into a water pill. Water pills are a conventional dosage form in the prior art. The preparation scheme of water pills is prepared according to conventional means and will not be repeated here. The preparation method refers to the method for preparing liver-soothing and qi-soothing preparations described in the applicant's prior patent CN101461925B, and can refer to process 1 of the patent. The process adopts a method of directly crushing traditional Chinese medicine into fine powder to prepare the medicine.

[0050] Example 2

[0051] This embodiment provides a preparation method of a soothing liver and shunning qi preparation. The medicinal materials are the same as those in Example 1. The preparation method is as follows: It is prepared by referring to process 2 in the specification of patent CN101461925B, as follows:

[0052] (01) Take thirteen medicinal materials according to the above weight portions and set aside; take 2 / 3 weight portion (1 / 2 to 2 / 3 weight portion can be used in actual operation) of each medicinal material, grind it and pass it through a 100-mesh sieve (80 to 120 mesh sieve can be used in actual operation), and set aside the coarse powder and fine powder after sieving;

[0053] (02) Take the remaining 1 / 3 of the raw material of the medicinal material and grind it into coarse powder; mix the coarse powder and the coarse head, add an ethanol solution of 7 times the total weight of the coarse powder and the coarse head (6 to 8 times can be used in actual operation), soak at 50°C (40 to 60°C can be used in actual operation) for 60 minutes (30 to 90 minutes can be used in actual operation), and then perform the first reflux extraction for 2 hours (1 to 2 hours can be used in actual operation), then add an ethanol solution of 7 times the total weight of the coarse powder and the coarse head (6 to 8 times can be used in actual operation) for the second reflux extraction for 2 hours (1 to 2 hours can be used in actual operation), combine the extracts, recover ethanol under reduced pressure, filter, recover the medicinal residue, and concentrate the extract into extract I, wherein the volume fraction of the ethanol solution used in the extraction is 50% (45 to 65% can be used in actual operation);

[0054] (03) boiling the residue obtained after extraction with water for 2 to 3 times (2 times can be used in actual operation), with the amount of water added each time being 6 to 10 times the amount of the residue (8 times can be used in actual operation), each time for 1 to 3 hours (1.5 hours can be used in actual operation), combining the decoctions, filtering, concentrating the filtrate to an extract II with half the weight of the residue, combining extract I and extract II, adding the fine powder obtained in step S2-2, mixing, and obtaining the active ingredient of the drug;

[0055] (04) Adding pharmaceutical excipients to the active ingredient of the drug to prepare it into a clinically acceptable preparation. In this embodiment, the active ingredient of the drug is specifically prepared into a water pill, that is, the binder is water. The preparation type and preparation method are conventional methods in the prior art and are not described in detail here.

[0056] Example 3

[0057] This embodiment provides a method for preparing a soothing liver and shunning qi preparation. The medicinal materials are the same as those in Example 1. The general preparation process is as follows:

[0058] With reference to the drug composition of Example 1, take 13 medicinal pieces of Magnolia officinalis, Chuanxiong, Cyperus rotundus (vinegar-processed), White Peony Root, Bupleurum Root, Immature Citrus Aurantium (fried), Curcuma Radix, Citrus Foetida, Aucklandia Root, Tangerine Peel, Licorice, Corydalis (vinegar-fried), and Amaranthus chinensis, add volatile oil extractor, add 8 to 10 times of water (preferably 8 times of water) of medicinal material mass, intermittent distillation extraction for 1 to 8 hours, (preferably 3 to 6 hours, further preferably 6 hours), obtain distilled water phase, distilled oil phase and medicinal residues after extraction, then separate the distilled water phase, distilled oil phase and medicinal residues, and the distilled water phase is sieved through 200 mesh for standby use. Wherein, the specific operation mode of intermittent distillation extraction is: fierce fire distillation extraction for 10 to 20 minutes (preferably 10 minutes), adjust the heat to control the distillation system to be in a micro-boiling state for 10 to 20 minutes (preferably 10 minutes), and circulate according to the above program until the extraction process ends. The existing technology generally uses steam heating, and the heating power is controlled by controlling the steam pressure of the distillation equipment. High heat means that the heating steam pressure is controlled within the range of 0.04 to 0.06 MPa in actual operation, and slight boiling heating (low heat heating) means that the steam pressure is controlled within the range of 0.01 to 0.02 MPa.

[0059] After the intermittent distillation extraction is completed, the medicinal residue is decocted in water for two more times. The first time, the amount of water added is 6 to 8 times the weight of the medicinal material (preferably 7 times), and the decocting time is 2 to 3 hours (preferably 3 hours). The second time, the amount of water added is 6 to 8 times the weight of the medicinal material (preferably 7 times), and the decocting time is 2 to 3 hours (preferably 3 hours). Each time the decocting is performed, the medicinal liquid is passed through a 160-200 mesh sieve (preferably a 200 mesh sieve), and the distilled water phase and the two decoctions are combined for later use (hereinafter referred to as the extract).

[0060] The extract and distilled oil phase are used to make various preparations. Among them, the distilled oil phase needs to be encapsulated with an inclusion agent; the extract needs to be concentrated and dried. The above are all common steps in the preparation process.

[0061] The method of using an inclusion agent to carry out inclusion treatment on the distilled oil phase is as follows: take 3 to 5 times the mass of hydroxypropyl-β-cyclodextrin of volatile oil, dissolve it in 3 to 5 times the mass of water of hydroxypropyl-β-cyclodextrin; under stirring conditions of 40 to 60 rpm, add volatile oil at a speed of 1 to 2 ml / min, stir for 1.5 to 2.5 hours after the addition is completed, and obtain an inclusion compound solution; concentrate and dry until the water content is less than 5.0%, and then crush through an 80 to 100 mesh sieve to obtain an inclusion compound powder. Preferably, the inclusion agent is hydroxypropyl-β-cyclodextrin.

[0062] The specific process of extract concentration and drying is as follows: the extract is concentrated into a clear paste with a relative density of 1.20-1.25, and then a dry paste is obtained by drying, and the dry paste rate is 24%-27%; the dry paste is crushed and passed through an 80-100 mesh sieve to obtain ointment powder.

[0063] The specific preparation method is:

[0064] (01) Take 13 kinds of medicinal materials, including Magnolia officinalis, Chuanxiong, Cyperus rotundus (vinegar-processed), White Peony Root, Bupleurum Root, Immature Citrus aurantium (fried), Curcuma Radix, Citrus Foetida, Aucklandia Root, Tangerine Peel, Licorice Root, Corydalis Root (vinegar-fried), and Amaranthus, add them into a volatile oil extractor, add 8 times the weight of the medicinal materials of water, and perform intermittent distillation extraction for 6 hours. After extraction, three parts, namely, distilled water phase, distilled oil phase, and medicinal residue, are obtained. The distilled water phase, distilled oil phase, and medicinal residue are then separated, and the distilled water phase is passed through a 200-mesh sieve for later use. The specific operation method of intermittent distillation extraction is: distillation extraction with high heat for 10 minutes, lowering the heat and slightly boiling for 10 minutes, and repeating the above procedure until the extraction process is completed.

[0065] (02) After the intermittent distillation extraction, the residue was decocted twice. The first time, 7 times the weight of the medicinal material was added, and the decocted for 3 hours. The second time, 7 times the weight of the medicinal material was added, and the decocted for 3 hours. Each time, the medicinal liquid was filtered through a 200-mesh sieve, and the distilled water phase and the second decoction liquid were combined to obtain the extract for use.

[0066] (03) Preparation of inclusion compound powder of distilled oil phase: Take 4 times the mass of hydroxypropyl-β-cyclodextrin of distilled oil phase, dissolve it in 4 times the mass of water of hydroxypropyl-β-cyclodextrin, add the distilled oil phase dropwise at a rate of 1-2 ml / min under stirring condition of 50 rpm, stir for 2 hours after the addition is completed to obtain inclusion compound solution, dry the inclusion compound solution until the water content is less than 5.0%, and then grind it through an 80-mesh sieve to obtain inclusion compound powder;

[0067] (04) The extract is subjected to conventional concentration and drying treatment. First, the extract is concentrated to an extract with a relative density of 1.20 to 1.25 (30 to 70°C, measured by a Pomeranian gravimeter). The concentrated material is then dried to obtain a dry paste, which is then crushed with a water-cooled pulverizer and sieved through an 80-mesh sieve for later use to obtain an ointment powder.

[0068] More specifically, the process of preparing the dry paste can be carried out by the following method:

[0069] Take the extract and start the single-effect concentrator, with the vacuum degree ≤-0.09Mpa, the temperature ≤75°C, and the steam pressure ≤0.30Mpa. Filter the extract through a bag filter with a mesh size of 250 and transfer it into the single-effect concentrator to concentrate it to a relative density of 1.20-1.25 (30-70°C, measured by a Pomeranian specific gravity meter). Then, the extract flows into the belt dryer at a speed of 200kg / h. The heating temperature of the first section of the belt dryer is set at 90-100°C; the heating temperature of the second section is set at 70-80°C; the heating temperature of the third section is set at 50-60°C. The dry paste after drying in the third section is collected, and the dry paste rate is 24%-27%.

[0070] (05) Granulation: Take the inclusion powder, ointment powder, cross-linked polyvinylpyrrolidone, microcrystalline cellulose and pregelatinized starch, mix and granulate them, and then mix and compress them with magnesium stearate to obtain liver-soothing and qi-relieving tablets. The auxiliary materials and dosage ranges used in the preparation of tablets are: 4-8 parts of cross-linked polyvinylpyrrolidone (6 parts in the specific experiment), 10-20 parts of microcrystalline cellulose (15 parts in the specific experiment), and 0.75-1.5 parts of magnesium stearate (1.35 parts in the specific experiment). In the dry granulation step, pregelatinized starch (Part IV of the "Chinese Pharmacopoeia" (2010 edition)) is used only as a filling material. Pregelatinized starch is added according to the weight of other materials in the actual preparation process to ensure the established total amount of materials.

[0071] Correspondingly, based on this embodiment, those skilled in the art can also select appropriate preparation excipients and prepare them together with inclusion compound powder (or inclusion compound solution), extract, etc. according to the needs of dosage form selection, and prepare them into tablets, granules, capsules, oral liquids, etc., which will not be repeated here. The main components for achieving the drug effect are the active pharmaceutical ingredients including inclusion compound powder and ointment powder, and these active pharmaceutical ingredients can be prepared into various dosage forms according to specific needs and in the conventional manner of the prior art.

[0072] Example 4

[0073] This embodiment provides a preparation method of a soothing liver and shunning qi preparation. The medicinal materials are the same as those in Example 3. The difference between the preparation method and Example 3 is that:

[0074] After the intermittent distillation extraction is completed, the residue is decocted in water for two more times. The amount of water added for the first time is 6 to 8 times the weight of the medicinal material (preferably 7 times), and the decoction is performed for 2 to 3 hours (preferably 3 hours). The amount of water added for the second time is 6 to 8 times the weight of the medicinal material (preferably 7 times). During the second decoction, the pH value of the system consisting of the residue and water is adjusted to 7.0 to 7.5 (preferably 7.2) with sodium hydroxide, and the decoction is performed for 2 to 3 hours (preferably 3 hours). Each time the decoction is performed, the medicinal liquid is passed through a 160 to 200 mesh sieve (preferably a 200 mesh sieve), and the distilled water phase and the two decoction liquids are combined for standby use (hereinafter referred to as the extract).

[0075] More specifically, step S3-2 further includes: during the second decoction, the pH value of the system consisting of the residue and water is adjusted to 7.2 with sodium hydroxide, and then decocted for 3 hours.

[0076] The remaining steps are the same as those in Example 3.

[0077] Test Example 1

[0078] This experimental example is an anti-anxiety / depression animal experiment, as follows:

[0079] (1) Experimental animals and groups

[0080] This experiment used SD rats (SPF grade, weight 160-200g) as experimental animals, both male and female. After one week of adaptive feeding, the rats were randomly divided into 11 groups, namely: blank control group, anxiety model group, anxiety medication group 1, anxiety medication group 2, anxiety medication group 3, anxiety medication group 4; depression model group, depression medication group 1, depression medication group 2, depression medication group 3, depression medication group 4, among which, there were 16 blank control groups (including 8 for depression control and 8 for anxiety control), and 8 in each of the remaining groups. The blank control group did not receive any treatment and was free to drink water and eat.

[0081] Depression modeling: The modeling methods of depression model group, depression drug administration group 1, depression drug administration group 2, depression drug administration group 3, and depression drug administration group 4 are as follows: the depression model was established by CUMS method stimulation for 5 weeks, and the stress stimulation methods included: 1) fasting and water deprivation for 24 hours; 2) plantar electrical stimulation, 3) wet bedding; 4) tilting the mouse cage 45°; 5) behavioral restraint; 6) continuous shaking of the mouse cage; 7) olfactory stimulation; one of the above seven methods was randomly selected to stimulate the target rats every day, and the stimulation method was not repeated in two consecutive days.

[0082] Anxiety disorder modeling: The modeling methods of the anxiety disorder model group, anxiety disorder drug administration group 1, anxiety disorder drug administration group 2, anxiety disorder drug administration group 3, and anxiety disorder drug administration group 4 are as follows: the anxiety rat model was established by the empty bottle drinking water stimulation method, and uncertain empty bottle stimulation was performed during the modeling period. The modeling period was 21 days, and the rats were free to eat and drink during the modeling period.

[0083] (2) Dosage regimen

[0084] Blank control group: normal feeding, no medication;

[0085] Anxiety disorder model group: Model was established and the mice were gavaged with an equal amount of normal saline;

[0086] Anxiety disorder administration group 1: intragastric administration of the drug prepared in Example 1, dissolved in physiological saline;

[0087] Anxiety disorder medication group 2: intragastric administration of the drug prepared in Example 2, dissolved in physiological saline;

[0088] Anxiety disorder administration group 3: intragastric administration of the drug prepared in Example 3, dissolved in physiological saline;

[0089] Anxiety disorder administration group 4: intragastric administration of the drug prepared in Example 4, dissolved in physiological saline;

[0090] Depression model group: Modeling, intragastric administration of equal volume of saline;

[0091] Depression medication group 1: intragastric administration of the drug prepared in Example 1, dissolved in physiological saline;

[0092] Depression medication group 2: intragastric administration of the drug prepared in Example 2, dissolved in physiological saline;

[0093] Depression medication group 3: intragastric administration of the drug prepared in Example 3, dissolved in physiological saline;

[0094] Depression medication group 4: intragastric administration of the drug prepared in Example 4, dissolved in physiological saline;

[0095] Dosage design: Based on the usage and dosage recorded in the instructions of the marketed product - Shugan Shunqi Pills, the equivalent dose for rats was calculated to be 1.33g crude drug / kg, and the drug was administered at this dose.

[0096] Dosage cycle: Administer once daily by gavage for 14 consecutive days.

[0097] (3) Experimental observations and results on depression

[0098] Effects of each group of drugs on the results of forced swimming test

[0099] After the last administration, the forced swimming test was performed: the rats in each experimental group were placed in a cylindrical glass container with a water depth of about 20 cm, so that the rats' limbs could not touch the bottom of the container, and the experimental water temperature of each group was kept consistent. The experimental rats were forced to swim for 6 minutes, and the total immobility time of the rats in each group after 4 minutes was recorded. The immobility time was defined as: the rats floated quietly in the water, without struggling or climbing the wall except for keeping their heads above the water. The experimental results are shown in Table 1.

[0100] Effects of each group of drugs on the sugar water preference results of rats

[0101] After the last administration, the rats in each group were subjected to a sugar water preference test. Before the experiment, sugar water training was first carried out. The method was: give each cage of rats two bottles of 1% sucrose solution to adapt to it for 24 hours, and replace the 1% sucrose solution with a bottle of pure water on the second day. After the sugar water training, fast for 12 hours and conduct a sugar water preference test. The method was: the rats were housed in a single cage, given 1 bottle of 1% sucrose solution and 1 bottle of pure water, and tested for 24 hours. To avoid position preference, the positions of the two bottles of water were exchanged every 12 hours. After the experiment, the respective consumption of 1% sucrose solution and pure water was recorded. The experimental results were calculated as follows: The formula for calculating sugar water preference is: Sugar water preference rate (%) = [sucrose solution consumption / (sucrose solution consumption + pure water consumption)] × 100%. The experimental results are shown in Table 1.

[0102] Effects of each group of drugs on the results of the rat tail suspension test

[0103] After the last administration, the tail suspension test was performed. During the experiment, the tail of each group of rats was fixed by 1 / 3, so that the head was suspended downward, and the immobility time of the rats was recorded. The immobility time was defined as: the body was vertically inverted, the four paws were clenched, and the tail suspension time was proportional to the degree of depression of the rats. The experimental results are shown in Table 1.

[0104] Table 1: Effects of each group of drugs on the forced swimming test, sugar water preference and tail suspension test of rats (x-±SD)

[0105]

[0106] Compared with the blank control group, # p<0.05, ## p<0.01; compared with the model group, * P<0.05, ** P<0.01, compared with depression medication group 3, △ p<0.05, △△ p<0.01;

[0107] From the above experimental results, we can know that:

[0108] The liver-soothing and qi-soothing composition for treating depression provided by the present invention can play an effective antidepressant effect, whether it is a direct powder preparation of crude drugs (Example 1), or a preparation of alcohol extraction of some medicinal materials (Example 2), or a combined preparation of volatile oil extracted from all medicinal materials by steam distillation (Examples 3 and 4). Among them, Example 2 extracts the medicinal materials by alcohol, and the obtained active pharmaceutical ingredients have a certain advantage over the effect of powdering crude drugs for the treatment of depression, while Examples 3 and 4 further make full use of the volatile oil components in the medicinal materials, and further improve the efficacy on the basis of Example 2.

[0109] At the same time, on the basis of Example 3, Example 4 of the present invention further improves the content of magnolol in the extract and the finished drug by adjusting the pH value of the system consisting of the drug residue and water to 7.2 with sodium hydroxide during the second decoction during the decoction of the drug residue after volatile oil extraction. After testing, at the same concentration level, during the preparation process of Example 4, the content of magnolol in the extract obtained after the extract was concentrated can reach 0.92 mg / g, which is greatly improved relative to the magnolol content of 0.71 mg / g in the embodiment. Therefore, it is speculated that during the second decoction of the drug residue, controlling the pH to be weakly alkaline is conducive to the dissolution of some effective ingredients in the drug residue, thereby further improving the efficacy.

[0110] In general, the original efficacy of the Shugan Shunqi composition is mainly to treat diseases such as indigestion. This technical solution has deeply developed the function of the combination and found that it also has ideal technical effects in the treatment of depression. Moreover, according to the specific implementation method of this test example, the modeling method of the experimental rats is completely unrelated to functional dyspepsia, gastrointestinal motility disorders, etc. This shows that the Shugan Shunqi composition can be used to treat symptoms unrelated to digestive system-related diseases, and the original use of the Shugan Shunqi composition has no relevance and technical inspiration for this new use. The Shugan Shunqi composition can play a role in the treatment of depression, which completely exceeds the expectations of those skilled in the art. On this basis, the inventor further developed ways to improve the effect of the Shugan Shunqi composition in treating depression, from crude drug powder preparations, to crude drug ethanol extract preparations, and then to crude drug distillation and decoction extraction preparations, which step by step improved the drug effect.

[0111] Effects of each group of drugs on the results of open field test in rats

[0112] After the last administration, an open field test was performed. The open field test was conducted in an open field test box with a height of 40 cm and a bottom area of ​​100 cm × 100 cm. In a quiet environment, the rats were placed in the central square of the open field test box. After they adapted for 3 minutes, the experiment began. The total movement path length and immobility time of each group of rats within 5 minutes were recorded. The experimental results are shown in Table 2.

[0113] Table 2: Effects of each group of drugs on the results of open field test in rats (x-±SD)

[0114] Total movement path (cm) Exercise time(s) Blank control group 174.25±24.55 254.21±32.84 Depression model group <![CDATA[105.78±23.42 ## ]]> <![CDATA[142.96±31.03 ## ]]> Depression medication group 1 <![CDATA[133.91±31.57 * ]]> <![CDATA[183.31±25.84 * ]]> Depression medication group 2 <![CDATA[146.23±19.85 * ]]> <![CDATA[205.46±24.19 * ]]> Depression medication group 3 <![CDATA[165.01±18.72 ** ]]> <![CDATA[231.15±21.30 ** ]]> Depression medication group 4 <![CDATA[171.29±24.07 **△ ]]> <![CDATA[242.35±28.61 **△ ]]>

[0115] Compared with the blank control group, # p<0.05, ## p<0.01; compared with the model group, * P<0.05, ** P<0.01, compared with depression medication group 3, △ p<0.05, △△ p<0.01;

[0116] From the above experimental results, it can be seen that the soothing liver and shunning qi composition for treating depression provided by the present invention, each group of drugs can have an effective antidepressant effect. At the same time, based on Example 3, the depression medication group 4 corresponding to Example 4 of the present invention has further improvement in the total movement path compared with the depression medication group 3.

[0117] (4) Anxiety disorder experimental observation and results: Effects of each group of drugs on the elevated plus maze experimental behavior of rats (anxiety disorder)

[0118] After the last administration, the elevated plus maze test was performed to evaluate the effects of each group of drugs on the results of the elevated plus maze test of rats. The performance of each group of rats within 5 minutes was recorded, including:

[0119] 1) the number of entries into the open arm (OE) and time (OT);

[0120] 2) the number of entries into the closed arm (CE) and time (CT);

[0121] According to the above data, the percentage of open arm entry times (OE%) and the percentage of open arm residence time (OT%) were calculated. The experimental results are shown in Table 3:

[0122] Table 3: Effects of each group of drugs on elevated plus maze behavior (x-±SD)

[0123]

[0124] Compared with the blank control group, # p<0.05, ## p<0.01; compared with the model group, * P<0.05, ** P<0.01, compared with anxiety medication group 3, △ p<0.05, △△ p<0.01;

[0125] It can be seen from the above experimental results that each group of drugs provided by the present invention can play an effective anti-anxiety effect. At the same time, based on Example 3, the anxiety medication group 4 has further improved OE% and OT% compared with the depression medication group 3. The original efficacy of the Shugan Shunqi composition is mainly to treat diseases such as dyspepsia, and there is no report on its efficacy in treating anxiety. According to the specific implementation method of this test example, the modeling method of the experimental rat (anxiety symptoms) is completely unrelated to functional dyspepsia, gastrointestinal motility disorders, etc. This shows that the action pathway and mechanism of the Shugan Shunqi composition for treating anxiety are not significantly related to digestive system-related diseases, and the original use of the Shugan Shunqi composition has no association and technical inspiration for this new use. It is very likely that the Shugan Shunqi composition is different from the mechanism of action of treating functional dyspepsia, gastrointestinal motility disorders, etc., to achieve the treatment of nervous system diseases such as anxiety. On this basis, the inventor further developed a way to improve the effect of the Shugan Shunqi composition in treating depression, from the crude drug powder preparation, to the crude drug ethanol extract preparation, and then to the crude drug distillation and decoction extraction preparation, step by step to improve the drug effect.

[0126] Test Example 2

[0127] A clinical trial was conducted to evaluate the efficacy and safety of Shugan Shunqi Pills in the treatment of patients with functional dyspepsia accompanied by anxiety or depression symptoms and liver depression and qi stagnation syndrome. The approved Shugan Shunqi Large Honey Pills were used as the drug of administration.

[0128] Case selection

[0129] 1) Diagnostic criteria:

[0130] (1) The diagnosis of traditional Chinese and Western medicine was formulated in accordance with the technical guidelines for clinical research on new Chinese medicines for functional dyspepsia (FD) issued by the Center for Drug Evaluation of the State Food and Drug Administration. The main symptoms of liver depression and qi stagnation syndrome are fullness and discomfort in the stomach or pain in the stomach; secondary symptoms are fullness in the flanks; irritability; heartburn or noisy feeling; frequent belching; sighing; attacks or aggravations due to emotional distress; pale red tongue, thin white fur, and stringy pulse. The diagnosis can be made by referring to the tongue and pulse if at least one of the main symptoms is present and any two of the secondary symptoms are present.

[0131] (2) Diagnosis of associated mood disorders:

[0132] A score of ≥5 on the Generalized Anxiety Scale (GAD-7) can be diagnosed as accompanied by anxiety symptoms;

[0133] A score of ≥5 on the PHQ-9 depression screening scale can be diagnosed as having depressive symptoms.

[0134] 2) Inclusion criteria: meeting the above diagnostic criteria;

[0135] For patients with anxiety symptoms, the score of Generalized Anxiety Scale (GAD-7) is ≥5 points and <19 points;

[0136] Those with depressive symptoms had a PHQ-9 depression screening scale score of ≥5 and <19 points;

[0137] Aged 18 to 70 years old, regardless of gender; voluntarily participate in clinical trials, give informed consent and sign the informed consent form; approved by the ethics committee of the hospital where they are located.

[0138] 3) Exclusion criteria include:

[0139] Those who do not meet the diagnostic criteria of Western medicine or traditional Chinese medicine; 13 C or 14C. Patients whose breath test results show that HP is positive; indigestion caused by organic diseases of the digestive system, such as peptic ulcer, Barrett's esophagitis, erosive gastritis (grade 2 or above), moderate to severe atrophic gastritis (pathology is moderate to severe atrophy, moderate to severe intestinal metaplasia, dysplasia), digestive tract tumors, digestive tract bleeding, hepatobiliary and pancreatic diseases, intestinal obstruction, inflammatory bowel disease, etc.; systemic diseases that affect digestive tract motility, such as diabetes, chronic renal insufficiency, connective tissue disease, nervous system lesions, etc.; patients with serious primary heart, brain, liver, lung, kidney, blood or serious diseases that affect their survival; patients with a history of abdominal surgery (except appendectomy and cesarean section); pregnant and lactating women, and those who have plans to have children in the near future; the blind, deaf, and dumb , intellectual disabilities, mental disorders and other physical disabilities; suspected or confirmed history of alcohol or drug abuse; those who have participated in other drug clinical trials in the past 3 months, or are taking drugs that may affect the effectiveness evaluation of the trial drugs (such as non-steroidal anti-inflammatory drugs, anticholinergic drugs, glucocorticoids, antidepressants, etc.); allergic constitution, such as a history of allergies to two or more drugs or foods, or known allergies to the ingredients of this drug; a history of liver and kidney dysfunction; other diseases that, according to the judgment of the researchers, reduce the possibility of inclusion or complicate inclusion, such as frequent changes in work environment, which are prone to loss to follow-up; patients diagnosed with major depression or severe anxiety and depression, and other people who are not suitable for participating in this study according to the judgment of the researchers.

[0140] 4) Exit criteria: patients who fail to take medication as prescribed, the dosage is less than 80% of the prescribed amount or exceeds 120% of the prescribed amount; patients who have adverse reactions and are not suitable to continue taking medication; patients whose condition worsens and affects their work or study; patients who have certain comorbidities, complications or special physiological changes and are not suitable to continue the trial; patients who use prohibited drugs specified in the protocol; patients who withdraw from the trial midway, or patients who do not explicitly request to withdraw from the trial but no longer accept medication and testing and are lost to follow-up.

[0141] 5) Exclusion criteria: those who did not meet the inclusion criteria and were mistakenly included; those who met the inclusion criteria but never took medication after inclusion, or those who had no follow-up records; those who used combined medications outside the prescribed range, especially those that had a significant effect on the trial drugs, affecting the effectiveness and safety judgment; those who violated the medication plan and used other Chinese and Western medicines for treatment.

[0142] 6) Termination criteria: serious safety issues occur during the trial; the trial finds that the drug treatment effect is too poor or even ineffective and has no clinical value; the drug marketing authorization holder requests termination (such as due to funding reasons, management reasons, etc.).

[0143] Clinical Data

[0144] A total of 50 patients with FD (functional dyspepsia) (33 with anxiety and 17 with depression) were selected as the research subjects, including 22 males and 28 females; age (46.90±12.08) years old; height (162.02±7.25) cm; weight (56.40±10.43) kg; TCM syndrome score (9.38±3.43) points; anxiety symptom score (6.12±3.34) points; depression symptom score (4.76±3.37) points.

[0145] Treatment

[0146] 1) Give the patient Shugan Shunqi Pills (National Medicine Standard No. Z20026802, manufacturer: Chongqing Xi'an Pharmaceutical Co., Ltd.) for oral administration, 9 grams (1 bag) at a time, 3 times a day, before breakfast, lunch and dinner.

[0147] The treatment course is 4 weeks. During the trial, the subjects should pay attention to a light diet, avoid smoking, drinking, spicy, cold, and greasy food; avoid emotional excitement and sulking.

[0148] 2) Combined medication and treatment

[0149] (1) During the trial, it is prohibited to use other drugs and treatments related to the treatment of this disease, including antacids, H2 receptor blockers, proton pump inhibitors, gastrokinetic drugs, antidepressants, calcium ion blockers, beta-blockers, anticholinesterase drugs, anticonvulsants, opioids, 5-HT4 receptor agonists, dopamine D2 receptor antagonists, non-steroidal anti-inflammatory drugs and macrolide antibiotics, as well as other Chinese and Western medicines that are clearly marked in the instructions as being able to affect the symptoms of functional dyspepsia and improve anxiety and depression symptoms. Treatments include but are not limited to acupuncture, massage, physical therapy, etc.

[0150] (2) The name of the medication (or other treatment name), dosage, frequency of use, and time of use of medications that must be continued for concurrent diseases or other treatments must be recorded in the research medical records. During the trial, the original type of medication, usage, and dosage should be kept unchanged as much as possible to facilitate analysis and reporting in the summary.

[0151] (3) If adverse events occur in the subjects during the trial, corresponding drugs may be used for treatment. However, the researchers need to evaluate whether the drugs used have an impact on the efficacy or safety evaluation of the trial drugs, and determine whether the subjects need to withdraw from the trial as appropriate.

[0152] (4) After the clinical trial is completed, patients who have not recovered should be treated according to current clinical routine methods.

[0153] Observation indicators

[0154] The patients' FD symptom scores, TCM syndrome scores, anxiety symptom scores, depression symptom scores, safety indicators, vital signs, and adverse events were recorded at the first visit and after treatment.

[0155] 1) FD symptom score: The subjects were scored according to their FD symptoms (0-2-4-6 points).

[0156] 2) TCM syndrome scoring: Each major symptom and secondary symptom of the subject was scored separately.

[0157] 3) Anxiety symptom score: The Generalized Anxiety Scale (GAD-7) was used for self-assessment.

[0158] 4) Depression symptom score: The Health Questionnaire-9 Depression Symptom Cluster Scale (PHQ-9) was used for self-assessment.

[0159] 5) Safety evaluation: the occurrence and severity of adverse reactions and adverse events. Changes in basic physical indicators such as heart rate, respiration, blood pressure, and body temperature.

[0160] Efficacy evaluation criteria

[0161] 1) Criteria for determining the efficacy of single symptom of FD:

[0162] Markedly effective: the original symptoms disappeared. Effective: the original symptoms were reduced by 2 levels. Improved: the original symptoms were reduced by 1 level. Ineffective: the original symptoms did not improve or worsened.

[0163] 2) FD efficacy evaluation criteria:

[0164] Cured: symptoms disappear. Significantly effective: symptom improvement rate ≥ 80%. Improved: symptom improvement rate ≥ 50%. Ineffective: symptoms do not improve significantly, or even worsen, symptom improvement rate < 50%.

[0165] Improvement rate = [(improvement) / total number of cases] × 100%; marked effectiveness rate = [(marked effect) / total number of cases] × 100%; cure rate = [(cure) / total number of cases] × 100%; total effectiveness rate = [(cure + marked effect + improvement) / total number of cases] × 100%.

[0166] 3) Criteria for determining the efficacy of TCM syndromes:

[0167] Clinical cure: TCM symptoms and signs disappear or basically disappear, and the syndrome score decreases by ≥95%. Marked effect: TCM symptoms and signs are significantly improved, and the syndrome score decreases by ≥70%. Effective: TCM symptoms and signs are improved, and the syndrome score decreases by ≥30%. Ineffective: TCM symptoms have no significant improvement, or even worsen, and the syndrome score decreases by <30%. Effective rate = [(effective) / total number of cases] × 100%; Marked effect = [(marked effect) / total number of cases] × 100%; Cure rate = [(cured) / total number of cases] × 100%; Total effective rate = [(cured + marked effect + effective) / total number of cases] × 100%.

[0168] 4) Evaluation of the efficacy of anxiety and depression symptoms:

[0169] Cured: returned to normal level. Remarkable effect: the severity of symptoms decreased by two levels. Effective: the severity of symptoms decreased by 1 level. Ineffective: the severity of symptoms did not improve, or even worsened. Effective rate = [(cured + marked effect + effective) / total number of cases] × 100%; Remarkable effect = [(cured + marked effect) / total number of cases] × 100%; Cure rate = [(cured) / total number of cases] × 100%.

[0170] 5) Overall efficacy evaluation:

[0171] Cured: FD cured + anxiety or depression symptoms improved effectively. Remarkably effective: FD markedly effective + anxiety or depression symptoms improved effectively. Improved: FD improved + anxiety or depression symptoms improved effectively. Ineffective: FD ineffective + anxiety or depression symptoms improved ineffectively. Improvement rate = [(improvement) / total number of cases] × 100%; Remarkably effective = [(remarkably effective) / total number of cases] × 100%; Cured rate = [(cured) / total number of cases] × 100%; Total effective rate = [(cured + markedly effective + improved) / total number of cases] × 100%.

[0172] Statistical processing

[0173] SPSS 22.0 statistical software was used. Two-sided test was used. The data were expressed as frequency or percentage (%) and the t test was used. The rank sum test was used for those that did not conform to the normal distribution. 2 P<0.05 was considered statistically significant.

[0174] Clinical trial results

[0175] The total number of clinical trials was 50, 46 of which were finally completed and 4 were withdrawn midway.

[0176] The efficacy of overall, FD, TCM symptoms, anxiety symptoms, and depression symptoms after treatment are shown in Tables 4 and 5.

[0177] Table 4: The efficacy of overall, FD, TCM symptoms, anxiety symptoms, and depression symptoms at the end of treatment (n, %)

[0178]

[0179] Table 5: FD single-item efficacy at the end of treatment (n, %)

[0180]

[0181] The experimental results showed that after treatment, the overall efficacy rate of patients, the total effective rate of FD, and the total effective rate of TCM syndrome efficacy were 60.87%, 63.04%, and 78.26%, respectively; the patients' anxiety and depression symptoms were significantly improved, with the total effective rates reaching 93.48% and 100%, respectively; the total effective rates of FD items such as postprandial fullness, early satiety, upper and middle abdominal pain, and burning sensation in the upper and middle abdomen were 58.70%, 86.96%, 73.91%, and 93.48%, respectively.

[0182] Comparison of FD symptoms, TCM syndromes, anxiety, depression symptoms self-rating scores and TCM single-item scores before and after treatment are shown in Tables 6 and 7. After treatment, the patients' FD symptoms, TCM syndromes, anxiety, depression symptoms self-rating scores and TCM single-item scores were all lower than those before treatment (all P < 0.05).

[0183] Table 6: Comparison of self-assessment scores of FD symptoms, TCM syndromes, anxiety and depression symptoms before and after treatment ( Compared with before treatment, * indicates P < 0.05)

[0184]

[0185] Table 7: Comparison of TCM single-item scores before and after treatment ( Compared with before treatment, * indicates P < 0.05)

[0186]

[0187] In summary, Shugan Shunqi Pills are safe and effective for functional dyspepsia accompanied by anxiety symptoms or depression symptoms (liver depression and qi stagnation syndrome), can improve patients' anxiety and depression symptoms and improve their quality of life, and are worthy of clinical promotion and application.

[0188] Test Example 3: Exploration of the preparation and processing methods of active pharmaceutical ingredients

[0189] (1) Exploration of intermittent distillation extraction

[0190] Study on the extraction process of distilled oil phase (preparation of distilled oil phase by intermittent distillation extraction):

[0191] The distilled oil phase extraction method of this experimental example was carried out in the manner of Example 3, except that the intermittent distillation extraction process was slightly changed, and 20 kg of medicinal materials were extracted (the composition of the medicinal materials was prepared according to the formula ratio of Example 3).

[0192] Test 1: Distill and extract under high heat for 15 minutes, adjust the heat to keep the distillation system in a slightly boiling state for 15 minutes, and repeat the above procedure until the extraction process is completed, a total of 6 hours. 23.0 mL of distilled oil phase is obtained, which is a clear oil with a strong aroma of distilled oil phase.

[0193] Test 2: Distill and extract under high heat for 10 minutes, adjust the heat to keep the distillation system in a slightly boiling state for 10 minutes, and repeat the above procedure until the extraction process is completed, a total of 4 hours. 22.1 mL of distilled oil phase was obtained, which was a clear oil with a strong aroma of distilled oil phase.

[0194] Test 3: Distillation was carried out under high heat for 4 hours. 19.5 mL of distilled oil phase was obtained, which was an emulsified oil with a strong aroma of distilled oil phase.

[0195] Test 4: Distillation was performed at a low boiling temperature for 4 hours. 15.2 mL of distilled oil phase was obtained, which was a clear oil with a strong aroma of distilled oil phase.

[0196] In the process of distillation and extraction of medicinal materials, if fierce fire distillation is used throughout the process, the efficiency of obtaining the distilled oil phase is not ideal, and the properties of the obtained distilled oil phase are turbid and of poor quality. If the method of micro-boiling distillation is used throughout the process, although the obtained distilled oil phase is clear, the amount of distilled oil phase obtained is too small. It can be seen that whether the medicinal materials are continuously distilled and extracted under more intense extraction conditions or milder extraction conditions, the amount of distilled oil phase obtained is not ideal (not exceeding 20mL). Alternating between fierce fire distillation extraction and micro-boiling distillation extraction can effectively increase the extraction amount of the distilled oil phase, and adding the distilled oil phase to the finished drug product can further enhance its anti-anxiety and anti-depression effects.

[0197] Therefore, when preparing the liver-soothing and gas-soothing preparation, the preferred method of extracting the distilled oil phase is: using a distillation fire that is intermittently circulated for 10-20 minutes and a total distillation time of 3-6 hours. The inventors have also preliminarily analyzed the reasons why the above method can increase the amount of distilled oil phase obtained, which may be as follows: Slow fire is to boil out the volatile oil in the medicinal materials, which will float or partially dissolve in hot water. After a certain amount is accumulated, fierce fire is used for boiling, and the accumulated volatile oil is concentrated and distilled back into the collector for cooling and collection. If fierce fire is always used for boiling, due to the large extractor, the amount of volatile oil is very small, and some volatile oil may stay on the wall of the extractor and is not easy to return to the collector, so the amount is relatively small. However, long-term fierce fire distillation may cause a compatibility reaction between the substances, resulting in turbidity of the volatile oil. Slow fire distillation is always used, and the distillation force is not enough, and it is not easy to distill and collect a large amount of volatile oil.

[0198] The experimental data of Test Example 1 show that the full utilization of volatile oils in medicinal materials has a significant effect on improving the therapeutic effect of drugs. How to further improve the amount and quality of volatile oils is the key to improving the therapeutic effect of the overall preparation. This test example studies the effect of distillation extraction on the amount and quality of volatile oils, creating conditions for improving the therapeutic effect of drugs.

[0199] (2) Exploration of pH value of decoction extraction

[0200] The preparation process of the extract (adjustment of pH value during the second decoction extraction) was studied in the following manner:

[0201] Test 1: Prepare the extract according to the optimal process of Example 4 of the present invention, wherein, during the second water decoction extraction, the pH value of the mixture of the drug residue and water is adjusted to 7.2 to prepare the final extract. After the extract is concentrated into an extract (60°C, density 1.30), the content of the monarch drug Magnolia officinalis (in terms of magnolol) in the extract, as well as the identification spots of costus root, citron, Corydalis yanhusuo, peony root, and liquorice are determined. The determination method refers to the quality standard of Shugan Shunqi Pills (WS-11169 (ZD-1169) -2002-2011Z) to detect the thin layer identification of costus root, citron, Corydalis yanhusuo, peony root, and liquorice, as well as the content of magnolol. The results of thin layer identification of costus root, citron, Corydalis yanhusuo, peony root, and liquorice show that the control and test spots are clear; the content of magnolol in the extract is 0.92 mg / g. Experimental studies have shown that ideal extraction effects can be achieved by adjusting the pH value of the extraction system to 7.0-7.5 before the second decoction and extraction, and the magnolia officinalis content in the extract can reach more than 0.9 mg / g.

[0202] Test 2: The extract was prepared according to Example 3 of the present invention. The difference between Example 3 and Example 4 is that during the second water decoction extraction, the pH value of the mixture of the residue and water was not adjusted, and the decoction extraction was performed directly. The experimental results showed that the control and test spots of costusroot and corydalis were clear, and the color was lighter than that of the extract prepared in "Test 1". The content of magnolol in the extract was 0.71 mg / g.

[0203] In summary, during the second decoction and extraction process, the pH value of the system consisting of the residue and water is adjusted to 7.0-7.5. This operation method is very effective in ensuring the transfer rate of costus root, citron, Corydalis yanhusuo, peony root, licorice and Magnolia officinalis, and increasing the content of the effective ingredients of Magnolia officinalis in the extract (i.e., the extract). In Test 2, the pH value of the system consisting of the residue and water in the second decoction and extraction was not adjusted, which would cause the content of Magnolia officinalis to decrease, and the spots for identification of costus root and Corydalis yanhusuo were relatively weak, indicating that the extraction method would affect the transfer rate of the effective ingredients in Magnolia officinalis, costus root and Corydalis yanhusuo.

[0204] The above experimental results show that in the stage of extract preparation, the pH value of the extraction system for the second decoction extraction needs to be adjusted to ensure the extraction rate of the effective ingredients. The content of the effective ingredients is one of the key technical points that affect the effect of the preparation. The inventors studied the effect of pH control on these effective ingredients during the water decoction extraction process, and further selected optimized conditions to improve the therapeutic effect of the preparation.

[0205] (3) Screening of inclusion agents

[0206] The preparation process of the inclusion compound powder (solution) is described in the best embodiment of Example 4. The types of inclusion agents were studied, and the effects of hydroxypropyl-β-cyclodextrin and β-cyclodextrin in preparing the inclusion compound were studied.

[0207] Solution 1: Dissolve 4 times the mass of the distilled oil phase of hydroxypropyl-β-cyclodextrin in 4 times the mass of water. Add the distilled oil phase dropwise at a rate of 1-2 ml / min under stirring at 50 rpm. Stir for 2 hours after the addition to obtain an inclusion complex solution. After inclusion, it becomes a transparent viscous liquid. After pulsating vacuum drying, it becomes a white flaky solid that is easy to break.

[0208] Scheme 2: Replace the hydroxypropyl-β-cyclodextrin in "Scheme 1" with β-cyclodextrin in equal amounts. β-cyclodextrin has poor solubility and the liquid after inclusion is a white paste. After standing, an oily substance floats on the upper layer. After pulsating vacuum drying, it becomes a white block solid.

[0209] The research results show that the encapsulation / solubilization effect of hydroxypropyl-β-cyclodextrin on the distilled oil phase of this product is better than that of β-cyclodextrin. Therefore, hydroxypropyl-β-cyclodextrin is selected to prepare the inclusion compound. The preparation of the inclusion compound will affect the compatibility of the distilled oil phase and the preparation as a whole, and thus affect the therapeutic effect of the drug.

[0210] In summary, the composition of the present scheme has shown therapeutic effects on depression and anxiety in a variety of preparation methods, and has obtained unexpected technical effects relative to the prior art. In addition, the preparation process of the combination and the way of obtaining the active ingredients of the medicine will affect the effect of the drug treatment of depression and anxiety to a certain extent. This technical scheme has studied the way to improve the efficacy of the drug from the powdered preparation of crude drug, to the ethanol extract preparation of crude drug, and then to the distillation of crude drug and the decoction extraction preparation. It is found that the method of distilling crude drug and then decoction extraction preparation makes full use of volatile oils and other effective ingredients, and can obtain the most ideal therapeutic effect. In addition, the method of distilling crude drug and then decoction extraction preparation is adopted, the parameters of intermittent distillation extraction are controlled, the pH value of the second decoction extraction is controlled, and the inclusion agent of the distilled oil phase is selected, which plays a very critical role in improving the acquisition amount and quality of the key effective ingredient volatile oil, improving the extraction amount of the active ingredients of the medicinal materials, and the compatibility of the volatile oil and the preparation, further ensuring the effect of more optimized treatment of depression and anxiety, and the application effect is more significant.

[0211] The above is only an embodiment of the present invention, and the common knowledge such as the known specific technical solutions and / or characteristics in the solution is not described in detail here. It should be pointed out that for those skilled in the art, several modifications and improvements can be made without departing from the technical solution of the present invention, which should also be regarded as the protection scope of the present invention, and these will not affect the effect of the implementation of the present invention and the practicality of the patent. The scope of protection required by this application shall be based on the content of its claims, and the specific implementation methods and other records in the specification can be used to interpret the content of the claims.

Claims

1. The use of a soothing liver and relieving qi composition in the preparation of an antidepressant drug, characterized in that: The soothing liver and relieving qi composition is prepared from the following medicinal raw materials in parts by weight: 25-35 parts of Magnolia officinalis, 25-35 parts of Chuanxiong, 25-35 parts of Cyperus rotundus, 25-35 parts of White Peony Root, 25-35 parts of Bupleurum Root, 25-35 parts of Citrus aurantium, 25-35 parts of Curcuma Radix, 25-35 parts of Citrus Hand, 25-35 parts of Aucklandia Root, 25-35 parts of Tangerine Peel, 20-30 parts of Licorice, 25-35 parts of Corydalis and 45-60 parts of Amaranthus; Preferably, the liver-soothing and qi-relief composition is made of the following medicinal raw materials in the following parts by mass: 31.4 parts of Magnolia officinalis, 31.4 parts of Chuanxiong, 31.4 parts of Cyperus rotundus, 31.4 parts of White Peony Root, 31.4 parts of Bupleurum Root, 31.4 parts of Citrus aurantium, 31.4 parts of Curcuma aromatica, 31.4 parts of Citrus citrus hand, 31.4 parts of Aucklandia lappa, 31.4 parts of Tangerine peel, 23.55 parts of Licorice, 31.4 parts of Corydalis yanhusuo and 58.85 parts of Amaranthus grandiflora.

2. Use of the liver-soothing and qi-soothing composition in the preparation of a drug for improving, assisting in the treatment or treating functional dyspepsia associated with depression, characterized in that: The soothing liver and relieving qi composition is prepared from the following medicinal raw materials in parts by weight: 25-35 parts of Magnolia officinalis, 25-35 parts of Chuanxiong, 25-35 parts of Cyperus rotundus, 25-35 parts of White Peony Root, 25-35 parts of Bupleurum Root, 25-35 parts of Citrus aurantium, 25-35 parts of Curcuma Radix, 25-35 parts of Citrus Hand, 25-35 parts of Aucklandia Root, 25-35 parts of Tangerine Peel, 20-30 parts of Licorice, 25-35 parts of Corydalis and 45-60 parts of Amaranthus; Preferably, the liver-soothing and qi-relief composition is made of the following medicinal raw materials in the following parts by mass: 31.4 parts of Magnolia officinalis, 31.4 parts of Chuanxiong, 31.4 parts of Cyperus rotundus, 31.4 parts of White Peony Root, 31.4 parts of Bupleurum Root, 31.4 parts of Citrus aurantium, 31.4 parts of Curcuma aromatica, 31.4 parts of Citrus citrus hand, 31.4 parts of Aucklandia lappa, 31.4 parts of Tangerine peel, 23.55 parts of Licorice, 31.4 parts of Corydalis yanhusuo and 58.85 parts of Amaranthus grandiflora.

3. The use according to any one of claims 1 or 2, characterized in that: The dosage form of the liver-soothing and qi-regulating composition is any one of pills, granules, tablets, oral liquids or capsules.

4. The use according to any one of claims 1 or 2, characterized in that: The liver-soothing and qi-regulating composition is prepared according to the following method: S1-1: Take each medicinal material according to the formula, grind each medicinal material and pass it through an 80-120 mesh sieve, mix them evenly, and obtain the active ingredient of the medicine; S1-2: Adding pharmaceutical excipients to the active ingredient of the drug to prepare it into a clinically acceptable oral preparation.

5. The use of the soothing liver and relieving qi composition according to claim 1 in the preparation of antidepressant drugs, characterized in that: The liver-soothing and qi-regulating composition is prepared according to the following method: S2-1: Take thirteen medicinal materials according to the formula and set aside; S2-2: 1 / 2 to 2 / 3 of the weight of each medicinal material is crushed into fine powder through a 80-120 mesh sieve, and the coarse powder and fine powder after sieving are set aside separately; S2-3: Grind the remaining medicinal materials into coarse powder; S2-4: the coarse powder and the coarse head are mixed, an ethanol solution of 6 to 8 times the total weight of the coarse powder and the coarse head is added, and the mixture is immersed at a temperature of 40 to 60° C. for 30 to 90 minutes, followed by a first reflux extraction for 1 to 2 hours, and then an ethanol solution of 6 to 8 times the total weight of the coarse powder and the coarse head is added for a second reflux extraction for 1 to 2 hours, the extracts are combined, ethanol is recovered under reduced pressure, filtered, the residue is recovered, and the extract is concentrated to extract I, wherein the concentration of the ethanol solution used in the extraction is 45 to 65%; S2-5: decoct the residue obtained after extraction with water for 2 to 3 times, with the amount of water added each time being 6 to 10 times the amount of the residue, for 1 to 3 hours each time, combine the decoctions, filter, and concentrate the obtained filtrate to extract II, combine extract I and extract II, add the fine powder obtained in step S22, mix well, and obtain the active ingredient of the drug; S2-6: Add pharmaceutical excipients to the active ingredient to prepare it into a clinically acceptable preparation.

6. The use of the soothing liver and relieving qi composition according to claim 1 in the preparation of antidepressant drugs, characterized in that: The liver-soothing and qi-regulating composition is prepared according to the following method: S3-1: Take thirteen medicinal materials according to the formula and set aside; S3-2: The medicinal raw materials are extracted by distillation to obtain a distilled water phase, a distilled oil phase and a medicinal residue, the medicinal residue is extracted by decocting in water to obtain a decoction, the decoction and the distilled water phase are combined to obtain an extract, the extract is concentrated into an extract, and the extract, the distilled oil phase and suitable excipients are prepared into a clinically acceptable oral dosage form.

7. Use of the liver-soothing and qi-regulating composition according to claim 1 in the preparation of antidepressant drugs, characterized in that: The liver-soothing and qi-regulating composition is prepared according to the following method: S4-1: 13 medicinal materials are taken according to the formula and set aside for use. The medicinal materials are subjected to distillation extraction to obtain a distilled water phase, a distilled oil phase and medicinal residues. The medicinal residues are subjected to water decoction extraction to obtain a decoction liquid, and the decoction liquid and the distilled water phase are combined to obtain an extract; S4-2: using an inclusion agent to carry out inclusion treatment on the distilled oil phase to obtain inclusion compound powder or inclusion compound solution; S4-3: After the extract is concentrated, it is prepared into a clinically acceptable oral dosage form with inclusion compound powder or inclusion compound solution and appropriate excipients.

8. Use of the liver-soothing and qi-regulating composition according to claim 6 or 7 in the preparation of antidepressant drugs, characterized in that: In S4-1, the method of extracting the medicinal residue by decoction in water is as follows: adding water 6 to 8 times the mass of the medicinal raw material for a first decoction extraction for 2 to 3 hours; adding water 6 to 8 times the mass of the medicinal raw material and adjusting the pH value to 7.0 to 7.5, and performing a second decoction extraction for 2 to 3 hours.

9. Use of the liver-soothing and qi-regulating composition according to claim 6 or 7 in the preparation of antidepressant drugs, characterized in that: In S4-1, the distillation extraction adopts an intermittent distillation extraction method, and the intermittent distillation extraction is performed alternately by fierce fire distillation and slight boiling distillation; Preferably, the intermittent distillation extraction uses water or alcohol solution as the extraction solvent; preferably, the total extraction time is 1 to 8 hours; preferably, the extraction process of the intermittent distillation extraction is cyclically carried out in a manner of first 10 to 20 minutes of high-fire distillation extraction and then 10 to 20 minutes of micro-boiling distillation extraction.

10. Use of the liver-soothing and qi-regulating composition according to claim 6 or 7 in the preparation of antidepressant drugs, characterized in that: In S4-2, hydroxypropyl-β-cyclodextrin is used as an inclusion agent to carry out inclusion treatment on the distilled oil phase; Preferably, the inclusion treatment method is: take an inclusion agent of 3 to 5 times the mass of the distilled oil phase, dissolve it, and then add the distilled oil phase at a rate of 1 to 2 ml / min under stirring conditions of 40 to 60 rpm, and stir for 1.5 to 2.5 hours after the addition is completed to obtain an inclusion solution; concentrate and dry it to a moisture content of less than 5.0%, and then crush it through an 80 to 100 mesh sieve to obtain an inclusion powder.

Citation Information

Patent Citations

  • Oral administration medicament for treating depression

    CN101085306A

  • Medicament composition for treating hepatopathy and preparation method thereof

    CN101461925A

  • A pharmaceutical composition for treating mental depression

    CN101530599A

  • Liver-soothing and qi-regulating traditional Chinese medicine composition used for treating depression, and preparation method thereof

    CN103083505A

  • Medicament for treatment of depression

    CN103405719A